MSCCOP

		home :: clinical trials :: treatment trials :: clinical trials

		CLINICAL TRIALS

AVAILABLE CLINICAL TRIALS

Breast Clinical Trials
	Ref #	Title
Endocrine Therapy	CALGB 40503	ENDOCRINE THERAPY IN COMBINATION WITH ANTI-VEGF THERAPY: A RANDOMIZED, PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE THERAPY PLUS BEVACIZUMAB FOR WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER
Neo-Adjuvant	CALGB 40603	PHASE II STUDY OF CARBOPLATIN +/- BEVACIZUMAB TO NEOADJUVANT WEEKLY PACLITAXEL FOLLOWED BY DOSE- DENSE AC IN HORMONE RECEPTOR-POOR/HER2-NEGATIVE RESECTABLE
Node (+)	CTSU ACOSOG Z1071	A PHASE II STUDY EVALUATING THE ROLE OF SENTINEL LYMPH NODE SURGERY AND AXILLARY LYMPH NODE DISSECTION FOLLOWING PREOPERATIVE CHEMOTHERAPY IN WOMEN WITH NODE POSITIVE BREAST CANCER (T1-4, N1-2, M0) AT INITIAL DIAGNOSIS
Adjuvant	NSABP B46-I	A phase III clinical trial comparing the combination of TC plus Bevacizumab to TC alone and to TAC for women with node-positive or high-risk node-negative, HER2-negative breast cancer
1st Line recurrent or metastatic	CALGB 40502	A randomized phase III trial of weekly Paclitaxel compared to weekly nanoparticle albumin bound Nab-Paclitaxel or Ixabepilone combined with Bevacizumab as first line therapy for locally recurrent or metastatic breast cancer.
Neo-Adjuvant (HER 2+)	CALGB 40601	RANDOMIZED PHASE III TRIAL OF PACLITAXEL COMBINED WITH TRASTUZUMAB, LAPATINIB, OR BOTH AS NEOADJUVANT TREATMENT OF HER2-POSITIVE PRIMARY BREAST CANCER
Breast Cancer	ALTTO NCCTG N063D	ALTTO: ADJUVANT LAPATINIB AND/OR TRASTUZUMAB TREATMENT OPTIMISATION STUDY A RANDOMISED, MULTI-CENTRE, OPEN-LABEL, PHASE III STUDY OF ADJUVANT LAPATINIB, TRASTUZUMAB, THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ERBB2 POSITIVE PRIMARY BREAST CANCER
High Risk or Node Positive	CTSU E5103	This study evaluates the effectiveness of adding the monoclonal antibody bevacizumab (Avastin) to the standard chemotherapy regimen of doxorubicin, cyclophosphamide and paclitaxel to treat women with lymph node positive and high-risk lymph node negative breast cancer. Monoclonal antibodies can interfere with cancer growth in different ways by: targeting the blood vessels that feed tumors, thus blocking the cancer’s ability to grow and spread; killing the cancer cells; or delivering cancer-killing substances to the cancer cells. Bevacizumab is not FDA approved for use in breast cancer, although it is approved for use in colorectal cancer and has been studied extensively in other breast cancer clinical trials, with good results. Patients are randomized into three groups, one of which receives only the standard chemotherapy regimen; the second group receives standard chemotherapy plus bevacizumab for four cycles of treatment; the third group receives standard chemotherapy plus bevacizumab for four cycles, and then receives bevacizumab for an additional ten cycles.
Neo Adjuvant	CTSU ACOSOG Z1031	A RANDOMIZED PHASE III TRIAL COMPARING 16 TO 18 WEEKS OF NEOADJUVANT EXEMESTANE (25 MG DAILY), LETROZOLE (2.5 MG), OR ANASTROZOLE (1 MG) IN POSTMENOPAUSAL WOMEN WITH CLINICAL STAGE II AND III ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Adjuvant Node (-)	CTSU ECOG PACCT-1	This study tests patients for their risk of recurrence of breast cancer and then assigns them to a treatment regimen based on their risk; patient outcomes are then tracked. To be eligible, patients must have breast cancer that is either estrogen receptor positive or progesterone receptor positive and be candidates for receiving chemotherapy followed by five years of hormone therapy. Before treatment with chemotherapy or hormone therapy, an Oncotype DX Assay is completed. This test results in an Oncotype Recurrence score, which indicates the likelihood of the cancer recurring. Patients are assigned treatment according to their Oncotype Recurrence score. Physicians then choose which chemotherapy and/or hormone therapy each patient receives.